Lymphadenectomy for the management of endometrial cancer
Identifieur interne : 005806 ( Main/Exploration ); précédent : 005805; suivant : 005807Lymphadenectomy for the management of endometrial cancer
Auteurs : Katie May [Royaume-Uni] ; Andrew Bryant [Royaume-Uni] ; Heather O. Dickinson [Royaume-Uni] ; Sean Kehoe [Royaume-Uni] ; Jo Morrison [Royaume-Uni]Source :
- The Cochrane database of systematic reviews [ 1469-493X ] ; 2010.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Lymphadénectomie.
- étiologie : Lymphocèle, Lymphoedème.
- Adulte, Essais contrôlés randomisés comme sujet, Femelle, Humains, Qualité de vie, Tumeurs de l'endomètre.
English descriptors
- KwdEn :
- MESH :
- adverse effects : Lymph Node Excision.
- etiology : Lymphedema, Lymphocele.
- surgery : Endometrial Neoplasms.
- Adult, Female, Humans, Quality of Life, Randomized Controlled Trials as Topic.
Abstract
Endometrial carcinoma is the most common gynaecological cancer in western Europe and North America. Lymph node metastases can be found in approximately 10% of women who clinically have cancer confined to the womb prior to surgery and removal of all pelvic and para-aortic lymph nodes (lymphadenectomy) is widely advocated. Pelvic and para-aortic lymphadenectomy is part of the FIGO staging system for endometrial cancer. This recommendation is based on non-randomised controlled trials (RCTs) data that suggested improvement in survival following pelvic and para-aortic lymphadenectomy. However, treatment of pelvic lymph nodes may not confer a direct therapeutic benefit, other than allocating women to poorer prognosis groups. Furthermore, a systematic review and meta-analysis of RCTs of routine adjuvant radiotherapy to treat possible lymph node metastases in women with early-stage endometrial cancer, did not find a survival advantage. Surgical removal of pelvic and para-aortic lymph nodes has serious potential short and long-term sequelae and most women will not have positive lymph nodes. It is therefore important to establish the clinical value of a treatment with known morbidity.
To evaluate the effectiveness and safety of lymphadenectomy for the management of endometrial cancer.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2009. Cochrane Gynaecological Cancer Review Group Trials Register, MEDLINE (1966 to June 2009), Embase (1966 to June 2009). We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field.
RCTs and quasi-RCTs that compared lymphadenectomy with no lymphadenectomy, in adult women diagnosed with endometrial cancer.
Two review authors independently abstracted data and assessed risk of bias. Hazard ratios (HRs) for overall and progression-free survival and risk ratios (RRs) comparing adverse events in women who received lymphadenectomy or no lymphadenectomy were pooled in random effects meta-analyses.
Two RCTs met the inclusion criteria; they randomised 1945 women, and reported HRs for survival, adjusted for prognostic factors, based on 1851 women.
Meta-analysis indicated no significant difference in overall and recurrence-free survival between women who received lymphadenectomy and those who received no lymphadenectomy (pooled HR = 1.07, 95% CI: 0.81 to 1.43 and HR = 1.23, 95% CI: 0.96 to 1.58 for overall and recurrence-free survival respectively).
We found no statistically significant difference in risk of direct surgical morbidity between women who received lymphadenectomy and those who received no lymphadenectomy. However, women who received lymphadenectomy had a significantly higher risk of surgically related systemic morbidity and lymphoedema/lymphocyst formation than those who had no lymphadenectomy (RR = 3.72, 95% CI: 1.04 to 13.27 and RR = 8.39, 95% CI: 4.06, 17.33 for risk of surgically related systemic morbidity and lymphoedema/lymphocyst formation respectively).
We found no evidence that lymphadenectomy decreases the risk of death or disease recurrence compared with no lymphadenectomy in women with presumed stage I disease. The evidence on serious adverse events suggests that women who receive lymphadenectomy are more likely to experience surgically related systemic morbidity or lymphoedema/lymphocyst formation.
Url:
DOI: 10.1002/14651858.CD007585.pub2
PubMed: 20091639
PubMed Central: 4171003
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 003434
- to stream Pmc, to step Curation: 003433
- to stream Pmc, to step Checkpoint: 003353
- to stream PubMed, to step Corpus: 002B91
- to stream PubMed, to step Curation: 002B91
- to stream PubMed, to step Checkpoint: 002B91
- to stream Ncbi, to step Merge: 003879
- to stream Ncbi, to step Curation: 003879
- to stream Ncbi, to step Checkpoint: 003879
- to stream Main, to step Merge: 005856
- to stream Main, to step Curation: 005806
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lymphadenectomy for the management of endometrial cancer</title>
<author><name sortKey="May, Katie" sort="May, Katie" uniqKey="May K" first="Katie" last="May">Katie May</name>
<affiliation wicri:level="4"><nlm:aff id="A1">Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
<settlement type="city">Oxford</settlement>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Bryant, Andrew" sort="Bryant, Andrew" uniqKey="Bryant A" first="Andrew" last="Bryant">Andrew Bryant</name>
<affiliation wicri:level="1"><nlm:aff id="A2">Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Health and Society, Newcastle University, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dickinson, Heather O" sort="Dickinson, Heather O" uniqKey="Dickinson H" first="Heather O" last="Dickinson">Heather O. Dickinson</name>
<affiliation wicri:level="1"><nlm:aff id="A2">Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Health and Society, Newcastle University, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kehoe, Sean" sort="Kehoe, Sean" uniqKey="Kehoe S" first="Sean" last="Kehoe">Sean Kehoe</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Oxford Gynaecological Oncology Centre, Level 0, Oxford Cancer and Haematology Centre, Oxford, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Oxford Gynaecological Oncology Centre, Level 0, Oxford Cancer and Haematology Centre, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morrison, Jo" sort="Morrison, Jo" uniqKey="Morrison J" first="Jo" last="Morrison">Jo Morrison</name>
<affiliation wicri:level="4"><nlm:aff id="A1">Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
<settlement type="city">Oxford</settlement>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20091639</idno>
<idno type="pmc">4171003</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171003</idno>
<idno type="RBID">PMC:4171003</idno>
<idno type="doi">10.1002/14651858.CD007585.pub2</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">003434</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003434</idno>
<idno type="wicri:Area/Pmc/Curation">003433</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003433</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003353</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003353</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">002B91</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B91</idno>
<idno type="wicri:Area/PubMed/Curation">002B91</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002B91</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002B91</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002B91</idno>
<idno type="wicri:Area/Ncbi/Merge">003879</idno>
<idno type="wicri:Area/Ncbi/Curation">003879</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003879</idno>
<idno type="wicri:Area/Main/Merge">005856</idno>
<idno type="wicri:Area/Main/Curation">005806</idno>
<idno type="wicri:Area/Main/Exploration">005806</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Lymphadenectomy for the management of endometrial cancer</title>
<author><name sortKey="May, Katie" sort="May, Katie" uniqKey="May K" first="Katie" last="May">Katie May</name>
<affiliation wicri:level="4"><nlm:aff id="A1">Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
<settlement type="city">Oxford</settlement>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Bryant, Andrew" sort="Bryant, Andrew" uniqKey="Bryant A" first="Andrew" last="Bryant">Andrew Bryant</name>
<affiliation wicri:level="1"><nlm:aff id="A2">Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Health and Society, Newcastle University, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dickinson, Heather O" sort="Dickinson, Heather O" uniqKey="Dickinson H" first="Heather O" last="Dickinson">Heather O. Dickinson</name>
<affiliation wicri:level="1"><nlm:aff id="A2">Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Health and Society, Newcastle University, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kehoe, Sean" sort="Kehoe, Sean" uniqKey="Kehoe S" first="Sean" last="Kehoe">Sean Kehoe</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Oxford Gynaecological Oncology Centre, Level 0, Oxford Cancer and Haematology Centre, Oxford, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Oxford Gynaecological Oncology Centre, Level 0, Oxford Cancer and Haematology Centre, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morrison, Jo" sort="Morrison, Jo" uniqKey="Morrison J" first="Jo" last="Morrison">Jo Morrison</name>
<affiliation wicri:level="4"><nlm:aff id="A1">Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
<settlement type="city">Oxford</settlement>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Cochrane database of systematic reviews</title>
<idno type="eISSN">1469-493X</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Endometrial Neoplasms (surgery)</term>
<term>Female</term>
<term>Humans</term>
<term>Lymph Node Excision (adverse effects)</term>
<term>Lymphedema (etiology)</term>
<term>Lymphocele (etiology)</term>
<term>Quality of Life</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphadénectomie (effets indésirables)</term>
<term>Lymphocèle (étiologie)</term>
<term>Lymphoedème (étiologie)</term>
<term>Qualité de vie</term>
<term>Tumeurs de l'endomètre ()</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lymph Node Excision</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Lymphadénectomie</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term>
<term>Lymphocele</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Endometrial Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphocèle</term>
<term>Lymphoedème</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Quality of Life</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Qualité de vie</term>
<term>Tumeurs de l'endomètre</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P5">Endometrial carcinoma is the most common gynaecological cancer in western Europe and North America. Lymph node metastases can be found in approximately 10% of women who clinically have cancer confined to the womb prior to surgery and removal of all pelvic and para-aortic lymph nodes (lymphadenectomy) is widely advocated. Pelvic and para-aortic lymphadenectomy is part of the FIGO staging system for endometrial cancer. This recommendation is based on non-randomised controlled trials (RCTs) data that suggested improvement in survival following pelvic and para-aortic lymphadenectomy. However, treatment of pelvic lymph nodes may not confer a direct therapeutic benefit, other than allocating women to poorer prognosis groups. Furthermore, a systematic review and meta-analysis of RCTs of routine adjuvant radiotherapy to treat possible lymph node metastases in women with early-stage endometrial cancer, did not find a survival advantage. Surgical removal of pelvic and para-aortic lymph nodes has serious potential short and long-term sequelae and most women will not have positive lymph nodes. It is therefore important to establish the clinical value of a treatment with known morbidity.</p>
</sec>
<sec id="S2"><title>Objectives</title>
<p id="P6">To evaluate the effectiveness and safety of lymphadenectomy for the management of endometrial cancer.</p>
</sec>
<sec id="S3"><title>Search methods</title>
<p id="P7">We searched the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2009. Cochrane Gynaecological Cancer Review Group Trials Register, MEDLINE (1966 to June 2009), Embase (1966 to June 2009). We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field.</p>
</sec>
<sec id="S4"><title>Selection criteria</title>
<p id="P8">RCTs and quasi-RCTs that compared lymphadenectomy with no lymphadenectomy, in adult women diagnosed with endometrial cancer.</p>
</sec>
<sec id="S5"><title>Data collection and analysis</title>
<p id="P9">Two review authors independently abstracted data and assessed risk of bias. Hazard ratios (HRs) for overall and progression-free survival and risk ratios (RRs) comparing adverse events in women who received lymphadenectomy or no lymphadenectomy were pooled in random effects meta-analyses.</p>
</sec>
<sec id="S6"><title>Main results</title>
<p id="P10">Two RCTs met the inclusion criteria; they randomised 1945 women, and reported HRs for survival, adjusted for prognostic factors, based on 1851 women.</p>
<p id="P11">Meta-analysis indicated no significant difference in overall and recurrence-free survival between women who received lymphadenectomy and those who received no lymphadenectomy (pooled HR = 1.07, 95% CI: 0.81 to 1.43 and HR = 1.23, 95% CI: 0.96 to 1.58 for overall and recurrence-free survival respectively).</p>
<p id="P12">We found no statistically significant difference in risk of direct surgical morbidity between women who received lymphadenectomy and those who received no lymphadenectomy. However, women who received lymphadenectomy had a significantly higher risk of surgically related systemic morbidity and lymphoedema/lymphocyst formation than those who had no lymphadenectomy (RR = 3.72, 95% CI: 1.04 to 13.27 and RR = 8.39, 95% CI: 4.06, 17.33 for risk of surgically related systemic morbidity and lymphoedema/lymphocyst formation respectively).</p>
</sec>
<sec id="S7"><title>Authors’ conclusions</title>
<p id="P13">We found no evidence that lymphadenectomy decreases the risk of death or disease recurrence compared with no lymphadenectomy in women with presumed stage I disease. The evidence on serious adverse events suggests that women who receive lymphadenectomy are more likely to experience surgically related systemic morbidity or lymphoedema/lymphocyst formation.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Oxfordshire</li>
</region>
<settlement><li>Oxford</li>
</settlement>
<orgName><li>Université d'Oxford</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="May, Katie" sort="May, Katie" uniqKey="May K" first="Katie" last="May">Katie May</name>
</region>
<name sortKey="Bryant, Andrew" sort="Bryant, Andrew" uniqKey="Bryant A" first="Andrew" last="Bryant">Andrew Bryant</name>
<name sortKey="Dickinson, Heather O" sort="Dickinson, Heather O" uniqKey="Dickinson H" first="Heather O" last="Dickinson">Heather O. Dickinson</name>
<name sortKey="Kehoe, Sean" sort="Kehoe, Sean" uniqKey="Kehoe S" first="Sean" last="Kehoe">Sean Kehoe</name>
<name sortKey="Morrison, Jo" sort="Morrison, Jo" uniqKey="Morrison J" first="Jo" last="Morrison">Jo Morrison</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005806 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005806 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:4171003 |texte= Lymphadenectomy for the management of endometrial cancer }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20091639" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |